- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BONE BIOLOGICS CORPORATION: Bone Biologics Expands Trial Sites | 2 | GlobeNewswire (USA) | ||
| BONE BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 14.08. | Bone Biologics Corp - 10-Q, Quarterly Report | 12 | SEC Filings | ||
| 23.07. | BONE BIOLOGICS CORPORATION: Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities | 333 | GlobeNewswire (Europe) | BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets... ► Artikel lesen | |
| 16.07. | Bone Biologics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Bone Biologics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Bone Biologics enters into definitive agreement for $3.0M private placement | 1 | Seeking Alpha | ||
| 08.07. | BONE BIOLOGICS CORPORATION: Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 192 | GlobeNewswire (Europe) | BURLINGTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics," or the "Company"), a developer of orthobiologic products for spine fusion markets... ► Artikel lesen | |
| 19.05. | Bone Biologics extends rhNELL-1 protein shelf life to 29 months | 1 | Investing.com | ||
| 19.05. | Bone Biologics verlängert Haltbarkeit von Protein rhNELL-1 auf 29 Monate | 1 | Investing.com Deutsch | ||
| 14.05. | Bone Biologics Corp - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.01. | BONE BIOLOGICS CORPORATION: Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook | 467 | GlobeNewswire (Europe) | BURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets... ► Artikel lesen | |
| 23.12.25 | BONE BIOLOGICS CORPORATION: Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months | 398 | GlobeNewswire (Europe) | BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,292 | -0,30 % | Here's Why Teladoc's Integrated Care Business Deserves More Attention | ||
| SERNOVA BIOTHERAPEUTICS | 0,086 | +0,70 % | Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc. | Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection... ► Artikel lesen | |
| CERENOME | 1,910 | -5,45 % | Cerenome, Inc.: Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment | Capital will support continued CNSide commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,060 | -4,63 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 15,800 | +6,76 % | Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now | ||
| CO-DIAGNOSTICS | 1,120 | 0,00 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| QUIDELORTHO | 10,005 | +0,43 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,435 | 0,00 % | Veru Inc.: Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial | ||
| LIFEWARD | 7,120 | 0,00 % | Lifeward Ltd.: Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy | ||
| CLOVER HEALTH INVESTMENTS | 4,090 | -1,68 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 7,450 | -0,67 % | Senseonics sees activist investor take a major stake | ||
| TEMPEST THERAPEUTICS | 0,800 | 0,00 % | Tempest Therapeutics Announces Up to $7.5 Million Private Placement | BRISBANE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the "Company"), a clinical-stage biotechnology company pioneering the development of advanced in vivo... ► Artikel lesen | |
| NANO-X IMAGING | 0,724 | 0,00 % | Nano-X Imaging Ltd: Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica | Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (NASDAQ: NNOX) ("Nanox"), a leader in innovative... ► Artikel lesen | |
| IMUNON | 1,290 | +2,38 % | Imunon, Inc.: IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 |
Das Unternehmen BONE BIOLOGICS CORP kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,550 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BONE BIOLOGICS CORP finden Sie auf Wallstreet Online.